Synthetic adjuvants to potentiate the immune response against rAg85B by nasal route.
- 1Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC) Lengshuitan District, Yongzhou City, Hunan, 425000, China
Abstract
Respiratory infections remain a relevant global health concern nowadays. The rapid dissemination and high mutational ratio of some pathogens, amid human demographic drivers, increases their pandemic potential. On the other hand, some bacterial infections have re-emerged with new resistant variants, supporting the need of updated or more potent vaccines. The development of nasal vaccines, with the capacity to efficiently induce immune response at the respiratory tract and systemic compartments, constitutes an appealing strategy to tackle respiratory infections, including tuberculosis. In this work, two synthetic compounds, the ODN-39M and the peptide LALF32-51, are evaluated as nasal vaccine adjuvants for the Ag85B antigen from Mycobacterium tuberculosis. The capacity of such adjuvants to enhance the immune response at systemic and mucosal compartments following intranasal immunization was assessed in Balb/C mice. The ODN-39M was able to potentiate the immune response, showing preferentially a Th1 pattern. The vaccine preparation containing this CpG adjuvant plus Ag85B induces potent cell-mediated and high IgA specific antibody response in lungs, along with systemic immunity. A preliminary study of the interaction between the ODN-39M with the NALT immune cells shows the early recruitment of lymphoid cells, and the increase of CD69 activation marker, mainly in B and dendritic cells. Although further studies should be done to reach a deeper understanding of NALT functioning, including the development of local innate response, the current data enrich the scarce reports focused on this compartment and support the use of the ODN-39M as a potent and potentially safe adjuvant option for future nasal vaccines.
Related
- Evaluation of new adjuvants in enhancing the immune response to a candidate of Severe Fever with Thrombocytopenia Syndrome Virus vaccine.
- Exploring the role of readthrough-inducing molecule 2,6-diaminopurine to increase immune response against cancer cells
- Plant-Derived Saponin and Polysaccharide Vaccine Adjuvants: Structure-Activity Relationships and Immune-Enhancement Strategies.
- Repurposing amlodipine, fluoxetine, and escitalopram as non-antibiotic adjuvants: in vitro enhancement of ciprofloxacin and fluconazole activity against multidrug-resistant bacterial and candida clinical isolates.
- A Lymphomimetic Synthetic Immune Niche, Consisting of CCL21 and ICAM1, Accelerates the Expansion of Potent CAR T-cells
BibTeX
@misc{chen2026synthetic,
title = {{Synthetic adjuvants to potentiate the immune response against rAg85B by nasal route.}},
author = {R. Chen and C. Tan and W. Li and Y. Perera and Y. Lobaina},
howpublished = {bioRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.31.748287},
url = {https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Synthetic adjuvants to potentiate the immune response against rAg85B by nasal route.
AU - R. Chen
AU - C. Tan
AU - W. Li
AU - Y. Perera
AU - Y. Lobaina
PY - 2026
DA - 2026/08/31
PB - bioRxiv
DO - 10.64898/2026.08.31.748287
UR - https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1
AB - Respiratory infections remain a relevant global health concern nowadays. The rapid dissemination and high mutational ratio of some pathogens, amid human demographic drivers, increases their pandemic potential. On the other hand, some bacterial infections have re-emerged with new resistant variants, supporting the need of updated or more potent vaccines. The development of nasal vaccines, with the capacity to efficiently induce immune response at the respiratory tract and systemic compartments, constitutes an appealing strategy to tackle respiratory infections, including tuberculosis. In this work, two synthetic compounds, the ODN-39M and the peptide LALF32-51, are evaluated as nasal vaccine adjuvants for the Ag85B antigen from Mycobacterium tuberculosis. The capacity of such adjuvants to enhance the immune response at systemic and mucosal compartments following intranasal immunization was assessed in Balb/C mice. The ODN-39M was able to potentiate the immune response, showing preferentially a Th1 pattern. The vaccine preparation containing this CpG adjuvant plus Ag85B induces potent cell-mediated and high IgA specific antibody response in lungs, along with systemic immunity. A preliminary study of the interaction between the ODN-39M with the NALT immune cells shows the early recruitment of lymphoid cells, and the increase of CD69 activation marker, mainly in B and dendritic cells. Although further studies should be done to reach a deeper understanding of NALT functioning, including the development of local innate response, the current data enrich the scarce reports focused on this compartment and support the use of the ODN-39M as a potent and potentially safe adjuvant option for future nasal vaccines.
ER -